Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Macular degeneration

This article was originally published in The Gray Sheet

Executive Summary

Medicare Coverage Advisory Committee will convene Sept. 9 to review the current national non-coverage policy for ocular photodynamic therapy with verteporfin for age-related macular degeneration patients with occult and no classic subfoveal choroidal neovascularization as determined by a fluorescein angiogram. 1CMS review of the policy was announced July 25, pursuant to a May 27 settlement CMS reached with the American Council for the Blind and American Association of People with Disabilities in Washington, D.C. federal court (2"The Gray Sheet" June 2, 2003, p. 7). The suit was filed against CMS in August 2002...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT018776

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel